TNGX

TNGX

USD

Tango Therapeutics Inc.

$8.010+0.120 (1.521%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$7.890

最高价

$8.170

最低价

$7.470

成交量

2.98M

公司基本面

市值

1.1B

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

2.68M

交易所

NGM

货币

USD

52周价格范围

最低价 $1.03当前价 $8.010最高价 $9.7

相关新闻

GlobeNewswire

Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), today announced that it will report third quarter 2025 financial results on November 4, 2025 at 9:00am ET, before the open of the U.S.

查看更多
Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
Analyst Upgrades

Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $12

Guggenheim analyst Charles Zhu maintains Tango Therapeutics with a Buy and raises the price target from $10 to $12.

查看更多
Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $12
GlobeNewswire

Tango Therapeutics Announces $225 Million Financing

BOSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines,

查看更多
Tango Therapeutics Announces $225 Million Financing
GlobeNewswire

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49%

查看更多
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers